Company news

Dyne Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer

March 19, 2025

Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months

March 15, 2025

Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum

March 10, 2025

Dyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

February 26, 2025

Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference

February 13, 2025

Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

February 2, 2025

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

January 20, 2025

Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYN...

January 9, 2025

Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

January 8, 2025

Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8: 00 a.m. ET

January 7, 2025

Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

November 11, 2024

Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE™ Platform to Address Underlying Causes of Neuromuscular Diseases

October 8, 2024

Dyne Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines Conference

September 22, 2024

Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts

September 2, 2024

Dyne Therapeutics Announces Key Leadership Appointments

September 2, 2024

Dyne Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

August 28, 2024

Dyne Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

August 11, 2024

Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease

June 23, 2024

Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress

June 12, 2024

Dyne Therapeutics to Present at Jefferies Global Healthcare Conference

May 29, 2024

Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock

May 20, 2024

Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints

May 19, 2024

Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8: 00 a.m. ET

May 18, 2024

Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 1, 2024

Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium

March 26, 2024

Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer

March 26, 2024

Dyne Therapeutics Announces CEO Transition

March 24, 2024

Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days

March 12, 2024

Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

March 4, 2024

Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference

February 13, 2024

Dyne Therapeutics to Present at February Investor Conferences

January 31, 2024

Dyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

January 4, 2024

Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock

January 3, 2024

Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrating Promise of the FORCE™ Platform in Developing Therapeutics for Rare Muscle Diseases

January 2, 2024

Dyne Therapeutics to Host Virtual Event Tomorrow, January 3 at 8: 00 AM ET, to Present Initial Clinical Data from ACHIEVE and DELIVER Trials

January 1, 2024

Dyne Therapeutics to Present at November Investor Conferences

November 6, 2023

Dyne Therapeutics Reports Third Quarter 2023 Financial Results and Provides Update on Significant Progress for ACHIEVE and DELIVER Trials and Upcoming Clinical Milestones

October 29, 2023

Dyne Therapeutics to Present at October Investor Conferences

September 27, 2023

Dyne Therapeutics Receives FDA Orphan Drug Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

September 19, 2023

Dyne Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference

September 4, 2023

Dyne Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

August 2, 2023

Dyne Therapeutics to Present at Jefferies Healthcare Conference

May 31, 2023

Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-101

May 24, 2023

Dyne Therapeutics’ Preclinical Data Demonstrating FORCE™ Platform Delivery to CNS Featured in Oral Presentation at ASGCT Annual Meeting

May 16, 2023

Dyne Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

May 10, 2023

Dyne Therapeutics to Present at BofA Securities 2023 Healthcare Conference

May 2, 2023

Dyne Therapeutics to Present New Preclinical Data at ASGCT Annual Meeting Demonstrating FORCE™ Platform Delivery to CNS

May 1, 2023

Dyne Therapeutics Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy

March 22, 2023

Dyne Therapeutics Announces Presentations on its DM1 and DMD Programs at the 2023 Muscular Dystrophy Association Clinical & Scientific Conference

March 19, 2023

Dyne Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

March 1, 2023

← Newer news releases · Older news releases →

Decks

The 5 newest of 15 decks. Every deck is listed under its year.